Market Cap : 77.71 B | Enterprise Value : 69.3 B | PE Ratio : 24.49 | PB Ratio : 6.50 |
---|
NAS:VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Vertex Pharmaceuticals's net current asset value per share for the quarter that ended in Jun. 2022 was $30.68.
The historical rank and industry rank for Vertex Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vertex Pharmaceuticals was 1835.50. The lowest was 2.16. And the median was 12.11.
VRTX's Price-to-Net-Current-Asset-Value is ranked worse thanThe historical data trend for Vertex Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's Net Current Asset Value, along with its competitors' market caps and Net Current Asset Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Net Current Asset Value distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Net Current Asset Value falls into.
Vertex Pharmaceuticals's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2021 is calculated as
Net Current Asset Value Per Share | (A: Dec. 2021 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (9560.6 | - | 3332.5 | - | 0 | - | 0) | / | 254.479 |
= | 24.47 |
Vertex Pharmaceuticals's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2022 is calculated as
Net Current Asset Value Per Share | (Q: Jun. 2022 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (11503.5 | - | 3648.7 | - | 0 | - | 0) | / | 256.026 |
= | 30.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of GrahamÂ’s strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Upadhyay Suketu | director | 345 E. MAIN STREET WARSAW IN 46580 |
Garber Alan M | director | 3355 MILTON COURT MOUNTAIN VIEW CA 94040 |
Kearney Terrence C | director | IN CARE OF HOSPIRA, INC. 275 NORTH FIELD DRIVE LAKE FOREST IL 60045 |
Carney Lloyd | director | C/O MICROMUSE INC 139 TOWNSEND ST SAN FRANCISCO CA 94107 |
Mckenzie Diana | director | METLIFE 200 PARK AVENUE NEW YORK NY 10166 |
Bhatia Sangeeta N. | director | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Lee Yuchun | director | 170 TRACER LA. WALTHAM MA 02451 |
Ambrose Kristen | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Mcglynn Margaret G | director | C/O MERCK & CO INC ONE MERCK DRIVE PO BOX 100 WHITEHOUSE STATION NJ 08889-0100 |
Liu Joy | officer: SVP, General Counsel | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Bozic Carmen | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP BILLERICA MA 01820 |
Arbuckle Stuart A | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 |
Kewalramani Reshma | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Other Sources
By Zacks 2022-04-01
By Zacks 2022-03-28
By Zacks 2022-03-25
By Zacks 2022-03-25
By Zacks 2022-03-31
By Zacks 2022-03-29
By Zacks 2022-03-31
By Zacks 2022-03-25
By Zacks 2022-03-29
By Zacks 2022-03-30
By Zacks 2022-03-24
By Zacks 2022-03-28
By Zacks 2022-03-29
By Zacks 2022-03-30